Innovating For Patients
Trevena is an innovative biopharmaceutical company dedicated to delivering groundbreaking medicines to address the critical needs of patients with central nervous system (CNS) disorders.
About Us
Targeted and Innovative CNS Therapies
Trevena’s novel pipeline is based on Nobel Prize winning research and includes one FDA-approved product in the United States, OLINVYK™ (oliceridine) injection, and three differentiated investigational drug candidates.
| Program | Molecular Target | Therapeutic Target | Current Phase | PC | PH1 | PH2 | PH3 | NDA | Approved |
|---|---|---|---|---|---|---|---|---|---|
| OLINVYK™ (oliceridine) injection | Mu receptor | Acute pain | Approved | PC complete | PH1 complete | PH2 complete | PH3 complete | NDA complete | Approved in progress |
| TRV045 | S1P receptor | Diabetic neuropathic pain | PH1 | PC complete | PH1 in progress | PH2 not started | PH3 not started | NDA not started | Approved not started |
| TRV250 | Delta receptor | Acute migraine | PH1 | PC complete | PH1 in progress | PH2 not started | PH3 not started | NDA not started | Approved not started |
| TRV734 | Mu receptor | Opioid use disorder | PH1 | PC complete | PH1 in progress | PH2 not started | PH3 not started | NDA not started | Approved not started |
Please see Important Safety Information including Boxed Warning in the full prescribing information available at OLINVYK.com. The pipeline assets are investigational products not approved by FDA for sale or distribution in the U.S.
